Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238660 | 0.82 | OPRD1 (0.48) | SIGMAR1OPRD1AVPR1A | |
| SCHEMBL6346542 | 0.79 | SIGMAR1 (0.55) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL6346561 | 0.79 | SIGMAR1 (0.55) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL30484433 | 0.79 | SIGMAR1 (0.55) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL1588897 | 0.79 | SIGMAR1 (0.55) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL14154427 | 0.78 | SIGMAR1 (0.65) | SIGMAR1TMEM97CCR2 | |
| SCHEMBL30623485 | 0.78 | SIGMAR1 (0.69) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL29531860 | 0.77 | SIGMAR1 (0.52) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL17014522 | 0.75 | SIGMAR1 (0.50) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 | |
| SCHEMBL29204433 | 0.74 | SIGMAR1 (0.60) | SIGMAR1TMEM97OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664216-B2 | Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2356123-B1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | AVPR1A, OXTR, AVPR1B | SIGMAR1 123/4885TMEM97 257/4885OPRM1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.